Evidence map›Paper›PMID 42110558›Full record

ArticleFrontiers in pharmacology2026

Rubiadin, as a key metabolite of the Bushen Huoxue formula, promotes apoptosis of endometrial stromal cells and improves intrauterine adhesions by activating the AMPK/p53/p21 pathway.

Cong Shen, Chenyang Sha, Mengqi Yang, Yi Lin, Juanjuan Ma, Dongyi Shen, Baohua Zhang, Cong Qi, Qinhua Zhang, Xiaole Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Cong Shen *Department of Obstetrics and Gynecology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Chenyang Sha *Department of Obstetrics and Gynecology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Mengqi YangDepartment of Obstetrics and Gynecology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Yi LinDepartment of Obstetrics and Gynecology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Juanjuan MaDepartment of Obstetrics and Gynecology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Dongyi ShenDepartment of Obstetrics and Gynecology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Baohua ZhangDepartment of Obstetrics and Gynecology, Punan Branch of Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Cong QiDepartment of Obstetrics and Gynecology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Qinhua ZhangDepartment of Obstetrics and Gynecology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Xiaole ZhangDepartment of Obstetrics and Gynecology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Aim: This study aimed to identify the key metabolite of BSHX and to investigate its therapeutic effects and underlying mechanism against IUA, both Methods: Network pharmacology and molecular dynamics simulation were utilized to screen the metabolites of BSHX. Results: In IUA clinical tissues, the AMPK/p53/p21 pathway was significantly inhibited. Rubiadin dose-dependently activated the AMPK/p53/p21 pathway, promoted endometrial stromal cell apoptosis, and inhibited cell migration, invasion, and collagen synthesis Conclusion: Rubiadin, a key metabolite of the Bushen Huoxue formula, ameliorates intrauterine adhesions by activating the AMPK/p53/p21 pathway, which promotes the apoptosis of endometrial stromal cells and restores endometrial function. This study provides a pharmacological basis for using Rubiadin as a potential therapeutic agent for IUA.

Indexed as

AMPK-p53-p21 pathwayapoptosis of endometrial stromal cellsBushen Huoxue formulaintrauterine adhesionsRubiadin

Identifiers

PMID42110558
PMCPMC13153455

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.